Last viewed: ETNB

Prices are updated after-hours

ETNB

89bio, Inc.

ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

(0.0% 1d) (-16.4% 1m) (-42.4% 1y) (0.0% 2d) (0.0% 3d) (-0.3% 7d) (-100.0% volume)
Earnings Calendar: 2024-03-08
Market Cap: $ 845,595,549
http://www.89bio.com
Sec Filling | Patents | 20 employees

89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.

liver metabolic nash msa

add to watch list Paper trade email alert is off

Press-releases

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Published: 2024-04-17 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

|

Health Technology

| 0.0% | O: 0.0% H: 0.0% C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M

|

Health Technology

| -1.81% | O: -1.81% H: 0.0% C: 0.0%
biotech

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-05 (Crawled : 20:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| Email alert Add to watchlist
nasdaq grants

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| -15.54% | O: 0.45% H: 3.29% C: 0.53%
metabolic cirrhosis treatment fibrosis prime ema

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| -26.61% | O: -0.08% H: 1.71% C: -0.08%
metabolic fibrosis trial

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-08 (Crawled : 21:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| Email alert Add to watchlist
nasdaq grant

89bio to Participate in the Leerink Partners Global Biopharma Conference
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| -19.35% | O: 2.22% H: 2.25% C: 1.17%
conference biopharma global

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-06 (Crawled : 21:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| 16.36% | O: 1.48% H: 4.79% C: 1.09%
conference life sciences

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-05 (Crawled : 21:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| -3.47% | O: -14.49% H: 0.0% C: -2.98%
nasdaq grants

Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M

|

Health Technology

| 19.0% | O: -0.51% H: 0.37% C: 0.32%
MDGL | $222.26 -2.66% -2.8% 220K

|

Health Technology

| -4.68% | O: 1.29% H: 0.35% C: -3.04%
HEPA | $2.1118 -0.85% -1.43% 30K

|

Health Technology

| 0.96% | O: -0.48% H: 7.69% C: 1.44%
ALT | $6.89 -2.13% -2.03% 2.7M

|

Commercial Services

| -31.37% | O: -0.8% H: 6.02% C: 0.6%
ALNY | News | $145.16 -0.11% -0.19% 400K

|

Health Technology

| -21.07% | O: 0.46% H: 3.04% C: 2.67%
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| -13.37% | O: 1.19% H: 0.63% C: -0.72%
liver disease companies key growth market

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-19 (Crawled : 21:00) - globenewswire.com
ETNB | $8.88 -3.06% -2.92% 680K

|

Health Technology

| -12.81% | O: -0.37% H: 1.3% C: -5.37%
nasdaq grants

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001415889-24-007085	4	2024-03-06	2024-03-04	Buy	P	1350000	12431584
0000950170-24-022433	4	2024-02-28	2024-02-26	Sell	S	4477	486889
0000950170-24-019666	4	2024-02-24	2024-02-17	Sell	F	778	106609

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

59%

41%

Top 10 Gainers

AGBA | News | $1.03 157.5% 57.94% 120M

|

ZCMD | $1.45 5.84% 52.1% 2.3M

|

Commercial Services

INVO | $1.52 100.0% 51.13% 5M

|

Health Technology

ISPC | $0.421 97.65% 49.53% 37M

|

Professional, Scientific, and T...

WLGS | News | $0.5 45.65% 470K

|

OST | $0.509 23.81% 45.26% 90K

|

GDHG | $0.263 21.76% 40.66% 3.1M

|

XPON | News | $3.15 63.21% 37.74% 16M

|

TIRX | $0.8 65.02% 30.74% 58M

|

BNTC | News | $6.82 42.08% 30.64% 3.5M

|

Health Technology

Last 48 Hours Insiders Buying

ADMQ | $0.0532 -4.14% -40.18% 480K

|

| 10:30
AXR P 2400 | $22.17 2.69% 0.0% 5.5K

|

| 21:00
QCRH P 118 | $55.41 1.34% 1.31% 54K

|

| 18:01
VUZI P 7500 | $1.26 3.28% 3.17% 930K

|

Electronic Technology

| 18:00
RMCF | $3.5501 0.57% 2.22% 18K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar